Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Predictive Oncology Inc (POAI)

Predictive Oncology Inc (POAI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 20,191
  • Shares Outstanding, K 3,394
  • Annual Sales, $ 1,620 K
  • Annual Income, $ -12,660 K
  • EBIT $ -8 M
  • EBITDA $ -8 M
  • 60-Month Beta 1.35
  • Price/Sales 12.37
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -13.50
  • Most Recent Earnings $-4.52 on 11/14/25
  • Next Earnings Date 04/07/26
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical Information Systems

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.88 +53.35%
on 12/05/25
8.26 -27.96%
on 11/13/25
-0.60 (-9.16%)
since 11/11/25
3-Month
3.88 +53.35%
on 12/05/25
32.10 -81.46%
on 09/29/25
-8.30 (-58.25%)
since 09/11/25
52-Week
3.88 +53.35%
on 12/05/25
45.90 -87.04%
on 01/06/25
-5.91 (-49.85%)
since 12/11/24

Most Recent Stories

More News
Predictive Oncology Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement

PITTSBURGH, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a AI-driven drug discovery company that has expanded its business to include a digital asset strategy focused on...

POAI : 5.95 (+0.51%)
Predictive Oncology Reports Third Quarter 2025 Financial Results and Provides Update on Digital Asset Strategy

PITTSBURGH, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI) , an AI-driven drug discovery company that has expanded its business to include a digital asset strategy focused on...

POAI : 5.95 (+0.51%)
Predictive Oncology Announces Additions to Board and Leadership Team to Support Digital Asset Treasury Strategy

Appoints Shawn Matthews, CEO of DNA Holdings Venture, Inc., and Former CEO of Cantor Fitzgerald, to its Board of Directors Names Thomas McLaughlin and Sara Turken, JD, as Chief Investment Officer...

POAI : 5.95 (+0.51%)
Predictive Oncology Closes $343.5M Private Placements

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Predictive...

POAI : 5.95 (+0.51%)
Predictive Oncology Inc. Announces Closing of $343.5 Million in Private Placements to Initiate Digital Asset Treasury Strategy

Investment creates the world’s first Strategic Compute Reserve  Strategy complements Predictive Oncology’s AI/ML-driven drug discovery and development activities PITTSBURGH, Oct. 08, 2025...

POAI : 5.95 (+0.51%)
Predictive Oncology Inc. Announces Private Placements of $344 Million to Initiate a Digital Asset Treasury Strategy Focused on Aethir (ATH) Tokens

Shawn Matthews, CEO of DNA Holdings and Former CEO of Cantor Fitzgerald, will join the Board of Directors upon the closing of the private placements Predictive Oncology continues to execute on its...

POAI : 5.95 (+0.51%)
Predictive Oncology Announces 1-for-15 Reverse Stock Split

PITTSBURGH, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (Nasdaq: POAI), a leader in AI-driven drug development and discovery, today announced that it will effect a 1-for-15 reverse...

POAI : 5.95 (+0.51%)
Predictive Oncology and Every Cure Announce a Strategic Collaboration to Pursue Drug Repurposing for Cancer Patients

PITTSBURGH, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug development and discovery, and Every Cure, a leading nonprofit dedicated to identifying...

POAI : 5.95 (+0.51%)
Predictive Oncology Reports Second Quarter 2025 Financial Results and Provides Corporate Update

PITTSBURGH, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI) , a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive...

POAI : 5.95 (+0.51%)
Predictive Oncology Issues Shareholder Letter: Well Financed to Support Expanded U.S. Availability and E.U. Launch of ChemoFx® and Pursuit of Other High-Value AI-Driven Drug Discovery and Development Opportunities

$10 million securities purchase agreement provides efficient and flexible funding in support of strategic multi-million dollar growth initiatives Discussions underway to expand adoption of ChemoFx in the...

POAI : 5.95 (+0.51%)

Business Summary

Predictive Oncology Inc. is focused on applying artificial intelligence to personalized medicine and drug discovery. Its operating business unit consists of Helomics, TumorGenesis and Skyline Medical. Predictive Oncology Inc., formerly known as Precision Therapeutics Inc., is based in MINNEAPOLIS.

See More

Key Turning Points

3rd Resistance Point 6.77
2nd Resistance Point 6.38
1st Resistance Point 6.17
Last Price 5.95
1st Support Level 5.57
2nd Support Level 5.18
3rd Support Level 4.97

See More

52-Week High 45.90
Fibonacci 61.8% 29.85
Fibonacci 50% 24.89
Fibonacci 38.2% 19.93
Last Price 5.95
52-Week Low 3.88

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar